Can I read Enasidenib for IDH2-Mutated MDS on EtoBox?

Enasidenib for IDH2-Mutated MDS by Shwetanshu is a document available to read on EtoBox.

What is Enasidenib for IDH2-Mutated MDS about?

The AG221-C-001 trial investigated the efficacy and safety of enasidenib in patients with mutant IDH2 myelodysplastic syndromes, revealing that 53% of patients achieved an overall response with a median duration of 9.2 months. The study included 17 patients, most of whom had previously received hypomethylating agents, and reported no dose-limiting toxicities. Enasidenib was found to be well tolerated, suggesting its potential as a treatment option for patients with IDH2 mutations who have not responded to c

Author

Shwetanshu

Language

EN